DT03 Rec'd PCT/PTO 0 1 DEC 2004

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 443788201 US Express Mail Label Number

16.

Other items or information: unsigned declaration and application data sheet

1 December 2004

Date of Deposit

	O-1390-MOD U. S	. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER		
(REV 10-	96)		PC/4-32514A		
	TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)			
	DESIGNATED/ELECTED O	FFICE (DO/EO/US)	40.544.75		
	CONCERNING A FILING U		10/516633		
INTE	RNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED		
PCT/I	EP03/05762	2 June 2003 (02.06.03)	3 June 2002 (03.06.02)		
	OF INVENTION	_			
THE	USE OF SUBSTITUTED CYANOPYRR	ROLIDINES AND COMBINATION PR	REPARATIONS CONTAINING THEM		
	TREATING HYPERLIPIDEMIA AND AS ICANT(S) FOR DO/EO/US	SSOCIATED DISEASES			
	MES ET AL.				
Applic	ant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) tl	ne following items and other information:		
1. 🗵		cerning a filing under 35 U.S.C. 371.			
2.	This is a SECOND or SUBSEQUENT su	ubmission of items concerning a filing un	der 35 U.S.C. 371,		
3.	This express request to begin national exercises examination until the expiration of the ap	xamination procedures (35 U.S.C. 371(f)) at any time rather than delay		
4. 🗵	A proper Demand for International Prelin	ninary Examination was made by the 19	th month from the earliest claimed priority		
	date.		,		
5 . ⊠	 A copy of the International Application as a. is transmitted herewith (required 	s filed (35 U.S.C. 371(c)(2))	and Burney		
	b. As been transmitted by the Inter	rnational Bureau. (See Form PCT/IB/30	iai Bureau). 98)		
	c. is not required, as the application	n was filed in the United States Receiving	g Office (RO/US).		
6. L	A translation of the International Applicat	tion into English (35 U.S.C. 371(c)(2)).	(25 H C C 274(-)(2))		
1. E	, <u></u>	ed only if not transmitted by the Internation	(35 U.S.C.371(c)(3)). onal Bureau)		
	 b. have been transmitted by the Interest 	ernational Bureau.	,		
		he time limit for making such amendmer	nts has NOT expired.		
8. T	 d. ⊠ have not been made and will not A translation of the amendments to the c 		71 (c)(3))		
9.	An executed Declaration and Power of A	attorney (original or copy) (35 U.S.C. 371	(c)(4)).		
10.		national Preliminary Examination Report	under PCT Article 36 (35 U.S.C.		
	371(c)(5)).				
Items	11. to 16. below concern document(s) or	r information included.			
11.	An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.			
40 -	1 A	A			
12	An assignment document for recording.	A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.		
13. 🗵	A FIRST preliminary amendment.				
	A SECOND or SUBSEQUENT prelimina	ry amendment.			
14. 🗆	A substitute specification.				
45 -					
15. [_] A change of power of attorney and/or ad-	aress letter.			

	6633		INTERNATIONAL APPLICATION NO. ATTORNEYS I PC/Y-325.				OOCKET NUMBER					
17. X The following fees are submitted:									CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):												
Search Report has been prepared by the EPO or JPO \$950												
International preliminary examination fee paid to USPTO (37 CFR 1.482)												
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$790												
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO												
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)												
								\$	950			
ENTER APPROPRIATE BASIC FEE AMOUNT =												
Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).								\$		-		
CLAIMS	NUMBER FILI	ED N	NUMBER EXTR	Α		RATE						
Total claims Independent claims	23 -	20 =	3		X		18	\$	54			
			2		X	\$	88	\$	176			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 300 TOTAL OF ABOVE CALCULATIONS =									1 100			
Reduction of 1/2 for filin	n by small entity if	annlicable	Verified Small E	Entity S	tatam	ont must s	100 bo	\$	1,180			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).								\$				
	,					SUBTO	TAI =	\$	1,180			
Processing fee of \$130 for furnishing the English translation later than 20 30 months from									.,			
the earliest claimed priority date (37 CFR 1.492(f)).								\$				
			T	OTAL	NA	ΓΙΟΝΑL	FEE =	\$	1,180			
Fee for recording the en	closed assignment	(37 CFR 1.:	21(h)). The assi	ignmer	t mus	t be accon	npanied	•				
by an appropriate cover	sheet (37 CFR 3.2	8, 3.31). \$4					+	\$				
			TOTA	L FE	ES E	NCLOSE	ED =	\$	1,180			
									unt to be:	\$		
,									refunded			
					_	. .			charged	\$		
	amount of \$											
b. 🛛 Please charge duplicate copy	b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,180 to cover the above fees. A duplicate copy of this form is enclosed.											
c. 🛛 The Commission Deposit Account	oner is hereby auth nt No. 19-0134 in th	orized to cha	arge any addition Novartis.	nal fee	s whic	h may be	required,	or cred	dit any over	payment to		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Novartis Corporate Intelle One Health Plaz East Hanover, N	a, Building 104				ey for No. 36		3	_				